Answers are grounded in this paper and cite their sources.
Bioequivalence studies between erlotinib tablets 25 mg/150 mg "NK" and Tarceva® t1ablets 25 mg/150 mg were conducted in healthy male Japanese volunteers. As Tarceva® tablets are a highly variable drug, studies had an adaptive, open-label, randomized, two drug, and two-period crossover design. As there was a lack of published pharmacokinetic information for Tarceva® tablet 25 mg, the study was conducted after a preliminary examination. Two-stage adaptive design was included in this study, and an interim analysis for the bioequivalence assessment was performed after Study Period 1 by the Interim Analysis Decision Council, which made recommendations to the sponsor according to the interim analysis procedure. As for the continuation of the study, the number of subjects in Study Period 2 was determined based on the geometric mean ratio and intra-subject variability obtained in Study Period 1. As the test statistic calculated from AUCt and Cmax in the analysis after Study Period 1 exceeded the critical value corresponding to the significance level of the interim analysis and the null hypothesis was rejected, the bioequivalence of the two formulations was verified. There were no clear differences in the safety profile between the two formulations. Although the subject number setting of highly variable drug assessment is an important issue in generic drug development, the adaptive design seems to be a useful countermeasure to this.
No takes yet. Share an insight, caveat, or question.
Hida et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: